Zymeworks Inc Stock News

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu

The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are

Investing in small-cap stocks offers multiple advantages for those looking to diversify their portfolios with potential high-growth opportunities efficiently. Small-cap stocks strike a unique balance

VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu

The Bulls are back in charge on Wall Street. Major stock indices like the S&P 500 and Dow have powered to new highs recently, with the tech-heavy Nasdaq poised to follow.

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu

Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.

Unlocking the potential of small-cap stocks often reveals sky-bound potential. The three listed stocks in the article offer substantial growth opportunities.

As investors, small-cap stocks offer us the possibility of monumental returns. If you play your cards right, small-caps can deliver gains most blue chips could never match.

In the pulsating realm of small-cap stocks, a select few emerge as trailblazers, poised to revolutionize industries and redefine investment landscapes. Enter the triumphant trio of three under-the-rad

On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflati

We've all had the experience of emptying our pockets at day's end to find a collection of coins. Sure, you could cash them in at a Coinstar machine for some bills.

The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breakout.

When you hear the term “growth stocks,” you probably think of high-growth yet unprofitable companies diluting shareholders through secondary offerings just to fund more losses. But that doesn't al

The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Zymeworks Inc. (ZYME). While the effectiveness of this highly sought-after metric is questionable, the